Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


SARS-CoV-2 has a sweet tooth


To help understand why uncontrolled diabetes is a risk factor for severe COVID-19, Campos Codo et al. looked at the relationship between glycolysis and SARS-CoV-2 replication in monocytes. Glucose enhanced SARS-CoV-2 viral load and mRNA expression of pro-inflammatory cytokines and type I/III interferons in these cells in a dose-dependent manner. Pretreating human peripheral blood monocytes with metabolic inhibitors showed that these effects of glucose depend on mitochondrial reactive oxygen species (mtROS) and HIF1α. The transition to aerobic glycolysis in SARS-CoV-2-infected monocytes facilitated viral replication and the production of soluble mediators that may contribute to lung damage. Additional studies are needed to investigate the potential for therapeutic targeting of mtROS, HIF1α and glycolysis signalling while maintaining antiviral type I/III interferons.


Original article

  1. Campos Codo, A. et al. Elevated glucose levels favor Sars-Cov-2 infection and monocyte response through a Hif-1α/glycolysis dependent axis. Preprint at SSRN (2020)

    Article  Google Scholar 

Download references

Author information



Corresponding authors

Correspondence to Athena Cavounidis or Elizabeth H. Mann.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cavounidis, A., Mann, E.H. SARS-CoV-2 has a sweet tooth. Nat Rev Immunol 20, 460 (2020).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing